Cosmetic vs. Drug Claims: Where the FDA Draws the Line for Skincare Brands

The Cosmetic vs. Drug Boundary: How the FDA Defines It

The Federal Food, Drug, and Cosmetic Act (FDC Act) draws the cosmetic/drug boundary based on intended use — specifically, what the product claims to do. A cosmetic is defined as a product intended to be "applied to the human body for cleansing, beautifying, promoting attractiveness, or altering the appearance." A drug is defined as a product intended to "affect the structure or any function of the body."

Notice the critical distinction: cosmetics alter appearance; drugs affect structure or function. This is the entire regulatory divide, and it turns on the specific words used in product copy, on packaging, and in advertising.

The practical consequence for skincare brands is significant: a serum cannot claim to "rebuild collagen" (structural change) but can claim to "promote the appearance of firmer skin" (appearance change). A moisturizer cannot claim to "repair the skin barrier" (functional change) but can claim to "help the skin look more hydrated and resilient" (appearance change). The underlying biology may be the same — a well-formulated barrier-supporting moisturizer does affect the skin's function — but the copy must stay on the appearance side of the line.

When a Product Becomes Both Cosmetic and Drug

A product can simultaneously be a cosmetic and a drug if it is intended to accomplish both cosmetic and drug purposes. Fluoride toothpaste is the classic FDA example: it is a cosmetic (cleans teeth, whitens appearance) and a drug (prevents tooth decay — a disease). Anti-dandruff shampoo is both a cosmetic (cleans hair) and a drug (treats dandruff — a medical condition).

For skincare brands, the most common example is sunscreen: it is a cosmetic (applied to skin for appearance purposes) and a drug (prevents sunburn and, with broad-spectrum claims, may reduce the risk of skin cancer). Products that are both cosmetics and drugs must comply with requirements for both — including FDA monograph requirements for over-the-counter drug products.

This duality is why sunscreen copy requires particular care. "Protects skin from UV rays" is a drug claim (preventing sunburn). "Provides broad-spectrum SPF protection" is a regulated OTC drug claim governed by the FDA's sunscreen monograph. Copy for sunscreen products — whether standalone or as a skincare ingredient like SPF-containing moisturizers — must follow OTC drug advertising rules in addition to cosmetic rules.

Appearance Language: The Words That Keep You Compliant

Understanding appearance language is the foundational skill for writing compliant skincare copy. The words that signal cosmetic territory — "visibly," "the appearance of," "looks," "skin appears" — do more regulatory work than any other element of skincare copy. They are not hedging or weakness; they are precision.

Consider these three versions of the same claim:

• "Removes wrinkles" — drug claim (structural alteration; wrinkles are reduced, implying permanent change)
• "Reduces wrinkles" — ambiguous, likely drug claim (reduces implies a biological change)
• "Reduces the appearance of wrinkles" — cosmetic claim (the appearance is altered, not the wrinkle itself)

The third formulation is compliant; the first two are not. The key word "appearance" converts the claim from structural to visual. This is not a loophole or a legal fiction — it reflects what the product actually does. A retinol serum does not remove wrinkles (they return if use stops); it changes how wrinkles appear. The appearance language is more accurate than the unqualified drug claim, not less.

Words That Signal Cosmetic Territory (Use These)

• "Visibly reduces..." / "Visibly improves..."
• "Reduces the appearance of..."
• "Minimizes the look of..."
• "Skin appears more..."
• "The look of [fine lines / pores / dark spots] is reduced"
• "Leaves skin looking..." / "Skin looks..."
• "Gives skin the appearance of..."

Words That Signal Drug Territory (Avoid These)

• "Removes wrinkles" / "Eliminates fine lines"
• "Increases collagen production" / "Rebuilds collagen"
• "Repairs the skin barrier" (structural claim)
• "Stimulates cell regeneration" / "Promotes cellular renewal"
• "Heals" (any form — implies therapeutic function)
• "Treats [acne / rosacea / eczema / psoriasis]" — disease references
• "Reverses aging" (structural claim — aging reversal implies biological change)
• "Permanently reduces" (permanence implies structural change)

The Complete Cosmetic vs. Drug Claims Table

MoCRA (2022): What Changed and Why It Matters

Before MoCRA, the FDA's authority over cosmetics was significantly more limited than its authority over food and drugs. If a cosmetic was found to contain a harmful ingredient or to make drug claims, the FDA had to go to court to force a recall — it could not act unilaterally. This limitation meant enforcement was slower, more resource-intensive, and more uncertain than FDA enforcement in the food or drug categories.

MoCRA changed this in several key ways:

Mandatory Recall Authority

MoCRA gave the FDA the power to order mandatory recalls of cosmetic products without going to court. This is the most significant enforcement power change. Before MoCRA, recalls in the cosmetics space were voluntary — the FDA could request a brand pull a product, but couldn't force it. Now the FDA can order it. This makes the regulatory consequences of drug claims in cosmetic advertising more immediate and severe.

Facility Registration Requirements

MoCRA requires domestic and foreign cosmetic manufacturers and processors to register their facilities with the FDA. Brands selling cosmetics in the US must have their manufacturing facilities registered. This creates a traceable supply chain for FDA enforcement purposes — when a brand makes drug claims in its advertising, the FDA can now more easily identify and act against the specific facility producing the product.

Expanded Adverse Event Reporting

Cosmetic brands with more than $1 million in annual US sales must report serious adverse events — consumer health problems associated with their products — to the FDA within 15 business days. This reporting requirement creates a data trail that the FDA can use to identify products whose claims may be crossing into drug territory based on the effects consumers are experiencing.

Why This Matters for Skincare Copy

MoCRA doesn't change what claims are permitted — the cosmetic/drug boundary is the same before and after MoCRA. What it changes is the enforcement consequence of crossing that boundary. Before MoCRA, a skincare brand making drug claims risked an FDA warning letter and a protracted voluntary recall negotiation. After MoCRA, the FDA has the authority to act faster, more decisively, and without requiring the brand's cooperation for a recall.

High-Risk Ingredient Categories in Skincare Copy

Some skincare ingredients are inherently higher-risk from a copywriting compliance perspective because their mechanism of action is biological (affecting cell turnover, collagen synthesis, melanin production, etc.) and the temptation to describe those mechanisms in copy is strong. Understanding which ingredients require the most careful copy treatment helps brands and their copywriters allocate compliance attention appropriately.

Retinoids (Retinol, Retinaldehyde, Bakuchiol)

Retinoids are among the most heavily studied skincare ingredients and one of the most frequently cited examples of cosmetic/drug boundary violations. Retinol (over-the-counter) and tretinoin (prescription-only) both affect cell turnover — a biological function. Copy for retinol products frequently makes drug claims by describing this mechanism.

• Prohibited: "Stimulates cell renewal," "increases collagen production," "accelerates skin cell turnover"
• Compliant: "Helps reduce the visible appearance of fine lines," "skin looks smoother and more refined over time," "visibly improves skin texture"

AHAs and BHAs (Glycolic Acid, Salicylic Acid, Lactic Acid)

Alpha and beta hydroxy acids exfoliate by affecting the bonds between skin cells — a functional mechanism. Salicylic acid is particularly complex because it is both a cosmetic exfoliant and an FDA-approved OTC drug ingredient for acne treatment. When used for acne, salicylic acid advertising must comply with OTC drug monograph requirements; when used for general exfoliation, it's a cosmetic.

• Prohibited: "Dissolves dead skin cells," "resurfaces the skin," "treats acne at the cellular level"
• Compliant: "Gently exfoliates to reveal brighter-looking skin," "helps reduce the appearance of blemishes," "skin appears smoother and more even"

Niacinamide (Vitamin B3)

Niacinamide is one of the most versatile and well-researched skincare ingredients, with documented effects on sebum regulation, hyperpigmentation, barrier function, and fine lines. The research is extensive — which makes it tempting to cite mechanisms in copy. The compliance rule: cite visible outcomes, not biological mechanisms.

• Prohibited: "Regulates sebum production," "inhibits melanin transfer," "repairs the skin barrier"
• Compliant: "Helps reduce the look of pores," "visibly improves uneven skin tone," "skin appears more balanced and refined," "5% niacinamide for visible results"

Peptides

Peptide claims are one of the most common sources of skincare drug claims because peptides are often described in terms of what they signal the body to do. "Signals collagen production," "activates skin's natural repair mechanisms," "tells fibroblasts to produce more collagen" — these all describe biological activity and are drug claims.

• Prohibited: "Signals collagen synthesis," "activates cellular repair," "promotes skin regeneration"
• Compliant: "Helps skin appear firmer and more youthful," "skin looks visibly plumper," "targets the look of aging"

INCI Language and Concentration Claims

Skincare buyers in 2026 are increasingly ingredient-literate. They know the difference between retinol and retinaldehyde, between hyaluronic acid molecular weights, between niacinamide at 2% and 10%. Copy that demonstrates this knowledge — while staying within appearance-language boundaries — builds authority and converts the research-driven buyer.

Using INCI Names Correctly

INCI names are the internationally standardized ingredient names used in cosmetic labeling globally. Best practice for skincare copy is to include both the INCI name and the common name for key active ingredients: "Retinol (Vitamin A, 0.3%)" tells a more complete story than either "retinol" or "Vitamin A" alone. Pairing the INCI name with the common name and concentration creates the density of information that ingredient-literate buyers respond to — with no compliance risk.

Concentration Claims as Compliance-Safe Conversion Tools

Concentration callouts — "5% niacinamide," "10% vitamin C," "0.1% retinol" — are factual statements about what the product contains. They are not health claims. They justify premium pricing by signaling formulation seriousness, and they allow buyers to compare your product against alternatives on a factual basis. Including concentration claims is one of the most effective ways to write copy that converts without making any compliance-risky assertions.

The Shopify Payments Trap for Skincare Brands

One of the most common and painful operational surprises for skincare brands scaling on Shopify is the Shopify Payments prohibition on certain ingredient categories. This prohibition is enforced by Stripe (which processes Shopify Payments transactions) and is separate from FDA compliance — a product can be entirely FDA-compliant and still be prohibited from using Shopify Payments.

WriteLift flags this risk to all skincare clients during onboarding. It is not an FDA or ASA issue — it's a payment processor policy that can shut down a brand's revenue processing overnight. The fix is straightforward: use an alternative payment gateway for affected products. But brands that discover this restriction after listing and selling face frozen funds and revenue disruption that takes weeks to resolve.

UK and Australian Skincare Compliance Rules

United Kingdom

UK skincare advertising is governed by the ASA/CAP Code alongside the UK Cosmetic Products Regulation. The UK distinguishes between purely cosmetic products and products that make therapeutic claims — the latter are treated as medicinal products and require more stringent advertising compliance. Key UK-specific rules:

• "Natural" claims: no legal UK definition, but ASA requires substantiation that ingredients are naturally derived with minimal processing
• "Organic" claims: no UK cosmetics standard exists — brands must substantiate based on whichever standard they're claiming (COSMOS, Soil Association, etc.)
• "Cruelty-free": must be verifiable throughout the supply chain, not just finished product testing
• Environmental claims (biodegradable, sustainable, eco-friendly): CMA enforcement from April 2025 includes fines up to 10% of global turnover for greenwashing
• "Clinically proven" or "dermatologist approved": ASA requires substantiation that the described approval or proof exists

Australia

In Australia, the boundary between cosmetics and therapeutic goods is determined by the TGA. Products that make therapeutic claims — that they treat, prevent, or diagnose a condition — are regulated as therapeutic goods and must be listed on the ARTG. Products that make only cosmetic claims (appearance, hygiene, attractiveness) are regulated as standard cosmetics under lower-tier regulation.

Skincare brands targeting Australian consumers must: avoid "may help" language for any therapeutic claims (zero protection under TGA rules), avoid testimonials describing therapeutic outcomes, and verify that any "dermatologist-tested" or "clinically tested" claims have supporting documentation available on request.

Writing Compliant Skincare Copy That Converts

The most effective skincare copy in the market doesn't try to make drug claims — it uses ingredient authority, concentration specificity, formulation transparency, and precise appearance language to build the trust that drives conversion. Here's the framework:

The Four Elements of High-Converting Compliant Skincare Copy

1. Ingredient specificity with INCI names: "Retinol (Vitamin A, 0.3%) — the gold standard ingredient in anti-aging skincare" paired with "visibly reduces the appearance of fine lines" is more compelling than either alone — and entirely compliant.

2. Concentration callouts: "5% niacinamide — the concentration used in clinical research on visible pore reduction." Factual, specific, compliance-safe, and it does real selling work for the ingredient-literate buyer.

3. Precise appearance outcomes: "Skin looks visibly plumper after 4 weeks of consistent use" is specific enough to be meaningful without making a structural claim. Time-framing appearance outcomes ("after 4 weeks," "in 28 days") adds specificity that converts skeptical buyers.

4. Negative ingredient callouts: "Fragrance-free, alcohol-free, paraben-free, suitable for sensitive skin" — what the product does NOT contain is as important as what it does for the growing segment of buyers with sensitivities or ingredient avoidances. These are factual statements that require no health claims.

For more on WriteLift's approach to skincare copywriting for Shopify and Amazon, see the WriteLift skincare copywriting service. For the FTC liability framework that applies to skincare advertising, see our article on FTC copywriter liability for health product advertising.

Frequently Asked Questions